Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023

  • ID: 4307513
  • Report
  • Region: Global
  • 170 Pages
  • Kuick Research
1 of 4

FEATURED COMPANIES

  • 3M Company
  • Batavia Bioservices
  • DanDrit Biotech
  • Elios Therapeutics
  • Kiromic
  • Northwest Biotherapeutics
  • MORE

“Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023” report gives comprehensive insight on various clinical and non-clinical advancements in the global dendritic cell cancer vaccine market.  In recent years, dendritic cell cancer vaccines have emerged as new growth frontier for the companies involved in the research and development of drugs for the treatment of cancer. As per report findings, currently there are 53 dendritic cell cancer vaccines in clinical pipeline. Most of  the dendritic cell cancer vaccines are in preclinical phase followed by phase-II clinical trials.

“Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023” Highlights:

  • Global Dendritic Cell Cancer Vaccine Market Overview
  • Assessment of Dendritic Vaccines with Other Therapeutic Regimens
  • Global Dendritic Cell Vaccines Clinical Pipeline by Company, Indication & Phase
  • Marketed Dendritic Cell Vaccines Clinical Insight
  • Dendritic Cells Mechanizing Immune Response
  • Future Growth Opportunities

Cancer is the leading cause of death worldwide and with around 18 million to 20 million new cases emerging every year, it takes heavy toll on people life and property. The governments across the globe along with private sectors have invested heavily in cancer therapeutics, which will be on the rising curve given the factors that abnormally increase the concentration of carcinogens in the atmosphere like vehicular emissions, environmental degradation coupled with drastic lifestyle changes like leading a sedentary life, lack of exercise etc.

Meanwhile, the conventional cancer therapeutics has but failed to yield desired result. During chemotherapy or radiation therapy or hormonal treatments which are the working horse of the cancer treatment besides tumor cells, normal surrounding cells are also killed. The necrosis factors associated with the dying normal cells signals inflammatory response to kick in and take the immune system on hyper drive killing tumor cells as well as normal, healthy adjoining cells as a collateral damage. This brings out the biggest irony, that the body instead of fighting off the cancer becomes susceptible to plethora of other life-threatening abnormalities causing high morbidity.

Dendritic cell cancer vaccines have created a niche for themselves in the cancer market, because they enjoy some inherent biochemical properties which could only be envy by their peers. They are the best known antigen presenting cells, as their task is to bind to the antigen peptides with MHC molecules and activate CD4+ T cells or CD8+ T cells to elicit the desired innate and adoptive immunity. Their action with MHC molecule offers dendritic cells, the prerequisite specificity in targeting the tumor associated antigens of various cancer types and its sub-types. This has enabled dendritic cell cancer vaccines to offer a wide domain of therapeutic action.

The recent advancement in in situ dendritic cell production from its progenitor cells, its maturation enabling processes and its delivery techniques has added to their advantage. They are also known to generate memory T cells which could produce a heightened secondary immune response for future encounters with the tumor cells in case of tumor progression. As cancer cells are known to evade immune response by triggering regulatory T cells suppressing the immune system, dendritic cells come to the rescue as it antagonistically acts on immune checkpoint inhibitors like CLAT4 and CD25 mediated immune pathways, thereby breaking the host’s immune tolerance.

As dendritic cells are found to have a modulatory effect on almost all the parameters of the immune system, all other types of cancer vaccines are found to be administered in conjugation with dendritic cells cancer vaccine to have a synergistic effect on immune system against tumor growth. With further advancement in immunological studies, dendritic cells cancer vaccine will have a driving effect on cancer therapeutics which will have a lion’s share on cancer vaccine market.

Even though some technical concerns existed regarding in situ production of dendritic cells due to its low concentration in peripheral tissues, it has been successfully overcome with engineered dendritic cells which could now be produced in large number for mass scale vaccination programs. Simultaneous administration of regulating factors which facilitate dendritic cell survival and immune-modulator function holds the key for increased efficiency of cancer vaccine based on dendritic cell, the superspecialised sentinels of cancer immunotherapy, the title it truly deserves.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3M Company
  • Batavia Bioservices
  • DanDrit Biotech
  • Elios Therapeutics
  • Kiromic
  • Northwest Biotherapeutics
  • MORE

1. Advent of Dendritic Vaccine in Oncology

2. Cataloging towards Dendritic Cells

3. Dendritic Cells Mechanizing Immune Response
3.1 Antigen Appearance Leads to Cellular Immune Responses
3.2 Stacking of Distinct Antigens over Dendritic Cells
3.3 Dendritic Cells Source & Subsets
3.4 Trail towards Maturation
3.5 Stimulation Initiates Maturation
3.6 Migration to Lymph Node
3.7 Precision of Dendritic Cells Vaccination
3.8 Illustrations of Clinical Results among Varied Cancer
3.9 Quality Control
3.10 Immune Monitoring

4. Equipping Dendritic Cell Vaccines
4.1 Cross Presentation of CD4 T-CD8 T Cells
4.2 Strategies to Recruit, Mature & Load Dendritic Cells In Situ
4.3 Strategies to Activate NKT Cells

5. Assessment of Dendritic Vaccines with Other Therapeutic Regimens
5.1 Dendritic Cell Cancer Vaccine & Monoclonal Antibodies
5.2 Dendritic Cell Cancer Vaccine & Peptide Based Cancer Vaccine
5.3 Dendritic Cell Cancer Vaccine & Cytokine Based Cancer Vaccine
5.4 Dendritic Cell Cancer Vaccine & Antibody Drug Conjugate Based Cancer Vaccine

6. Dendritic Cell Cancer Vaccine Market & Clinical Insight
6.1 Some Trends Involving Dendritic Cells Cancer Vaccination
6.2 Dendritic Cell Cancer Vaccine Pipeline Overview

7. Undercurrents of Dendritic Cancer Vaccine Growth

8. Challenging Milieu for Dendritic Cancer Vaccine

9. Prospective Trajectories for Future

10. Dendritic Cell Vaccines Clinical Pipeline by Company, Indication & Phase
10.1 Research
10.2 Preclinical
10.3 Clinical
10.4 Phase I
10.5 Phase I/II
10.6 Phase II
10.7 Phase II/III
10.8 Phase III

11. Marketed Dendritic Cell Vaccines Clinical Insight
11.1 Sipuleucel-T (Provenge)
11.2 Dendritic Cell Vaccine (CreaVax-HCC,CreaVax-PC & CreaVax-RCC)
11.3 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

12. Competitve Landscape
12.1 3M Company
12.2 Activartis
12.3 Argos Therapeutics
12.4 Batavia Bioservices
12.5 Bellicum Pharmaceuticals
12.6 Creagene
12.7 DanDrit Biotech
12.8 DCPrime
12.9 Dendreon Corporation
12.10 Elios Therapeutics
12.11 ImmunoCellular Therapeutics
12.12 Immunicum
12.13 Kiromic
12.14 Medigene
12.15 Merck
12.16 Northwest Biotherapeutics
12.17 Glaxo Smith Kline
12.18 ImmunoCellular Therapeutics
12.19 SOTIO
12.20 Tella Incorporation
12.21 Theravectys
12.22 Vaxil BioTherapeutics

List of Figures:
Figure 1-1:  Advantages of Dendritic Cell Cancer Vaccine
Figure 2-1: Classification of Dendritic Cells
Figure 3-1: Principle of Dendritic Cell Cancer Immunotherapy
Figure 3-2: The Key Players Intricately Involved in Antigen Presentation & Immune Response Machinery
Figure 3-3: Process of Antigen-loading
Figure 3-4: Major Life Cycle Events of a Dendritic Cell
Figure 3-5: A Diagrammatic Representation of Dendritic Cell Plasticity
Figure 3-6: Action of Dendritic Cells on the Various Cancer Forms
Figure 4-1: The Arsenals in the Inventory of Dendritic Cells
Figure 5-1: Working Principle Targeted By Dendritic Cells & Monoclonal Antibodies
Figure 5-2: Working Principle Targeted by Dendritic Cells & Peptide Cancer Vaccines
Figure 5-3: Working Principle Targeted by Dendritic Cells & Cytokine Cancer Vaccine
Figure 5-4: Working Principle Targeted By Dendritic Cells & Antibody-Drug Conjugates Cancer Vaccines
Figure 6-1: Recent Trends in Dendritic Cell Vaccine
Figure 6-2: Global - Dendritic Cell Cancer Vaccine Clinical Pipeline by Phase (%), 2017 till 2023
Figure 6-3: Global - Dendritic Cell Cancer Vaccine Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 6-4: Global - Suspended Dendritic Cell Vaccine in Clinical Pipeline by Phase (%), 2017 till 2023
Figure 6-5: Global - Suspended Dendritic Cell Vaccine in  Pipeline by Phase (Number), 2017 till 2023
Figure 7-1: Factors Driving Dendritic Cell Cancer Vaccine
Figure 8-1: Challenges for Dendritic Cell Cancer Vaccine
Figure 12-1: Argos Therapeutics- Clinical Pipeline
Figure 12-2: Bellicum Pharmaceuticals Clinical Pipeline
Figure 12-3: DCPrime Clinical Pipeline
Figure 12-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 12-5: Immunicum Clinical Pipeline
Figure 12-6: Medigene Clinical Pipeline
Figure 12-7: Northwest Biotherapeutics Clinical Pipeline
Figure 12-8: SOTIO Clinical Pipeline

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 3M Company
  • Activartis
  • Argos Therapeutics
  • Batavia Bioservices
  • Bellicum Pharmaceuticals
  • Creagene
  • DanDrit Biotech
  • DCPrime
  • Dendreon Corporation
  • Elios Therapeutics
  • Glaxo Smith Kline
  • Immunicum
  • ImmunoCellular Therapeutics
  • Kiromic
  • Medigene
  • Merck
  • Northwest Biotherapeutics
  • SOTIO
  • Tella Incorporation
  • Theravectys
  • Vaxil BioTherapeutics
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll